Pharvaris shares jumped after the company reported positive late-stage trial results for its hereditary angioedema drug, deucrictibant XR.
The pivotal CHAPTER-3 Phase 3 study met its primary endpoint, cutting monthly attack rates by 83% versus placebo; in patients with HAE Type 1 or Type 2, the reduction was 87%.
All secondary efficacy endpoints were also met, and the drug was described as well tolerated with no treatment-related serious adverse events reported.
The company said the data will support regulatory submissions, including a planned U.S. NDA in the first half of 2027.
Hereditary angioedema is a rare genetic disorder that causes severe swelling attacks and can be life-threatening if the airway is affected.
Sources:
Pharvaris, pushing through trial pause, sees shares surge ...
Pharvaris shares spike as drug appears to prevent symptoms of rare disorder
News Releases - Pharvaris N.V.
Pharvaris stock surges 27% on positive trial data By Investing.com
Pharvaris stock gains on HAE drug meeting late-stage study goals
Why is Pharvaris stock surging today? By Investing.com
Pharvaris posts late-stage trial win for HAE drug (PHVS:NASDAQ)
Pharvaris (PHVS) Shares Rise on Positive Phase 3 Trial; Valuatio
Pharvaris (PHVS) Phase 3 Data Boosts Optimism Amid Unprofitable
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
Pharvaris' genetic disorder drug meets main goal in late-stage trial
Pharvaris Unveils CHAPTER-3 Phase 3 Topline Data and HAE Pipeline Milestones
Investor Relations - Pharvaris N.V.
Why Pharvaris (PHVS) Is Up 13.3% After RAPIDe-3 Success And ...